-+ 0.00%
-+ 0.00%
-+ 0.00%

Design Therapeutics Q2 EPS $(0.32) Beats $(0.34) Estimate

Benzinga·08/03/2026 12:04:28
Listen to the news
Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.34) by 5.88 percent. This is a 5.88 percent increase over losses of $(0.34) per share from the same period last year.